The pharmacological properties of the drug are reflected in the action of its components. Ascorbic acid helps slow down the excretion of barbiturates, sulfonamides and salicylates. Pyridoxine increases the decarboxylation of levodopa in peripheral tissues. Due to the combination of certain components (phenytoin, anticonvulsants), it is appropriate to buy epargriseovit to significantly reduce the risk of developing hypercalcemia. The presence of methotrexate, pyrimethamine, trimethoprim, triamterene, anticonvulsants and sulfasalazine reduces the absorption of folic acid. Oral contraceptives (estrogens) increase serum concentrations of vitamins C and A and also lead to a decrease in folic acid levels. The content of folic acid in sufficient quantities is an additional incentive to buy epargriseovit. Glucocorticosteroids, cimetidine, valproic acid, penicillamine, phenytoin, disulfiram, isoniazid, captopril, ethambutol, diuretics, mercaptopurine and tetracycline increase the excretion of zinc and reduce its content in the blood. Non-systemic antacids and tetracyclines reduce iron absorption.

Epargriseovit contains useful microelements (ascorbic acid, nicotinamide (vitamin PP), folic acid, cyanocolamin (vitamin B 12), which support the vital functions of the body. To ensure the flow of processes in the body at a high level, it will be reasonable and satisfactory to buy epargriseovit. increased need for vitamins and minerals during intense physical and mental activity.

IMMUNOBIOLOGICAL BIOLOGICAL PROPERTIES

Erythropoietin is a glycoprotein consisting of 165 amino acids, formed in the kidneys and stimulates the division and differentiation of erythroid precursors in the bone marrow. EPOVITEN for injection is a human erythropoietin preparation produced using recombinant DNA technology. The drug is produced by mammalian cells in which the human erythropoietin gene has been introduced, and therefore the sequence of amino acid residues is the same as that of isolated natural erythropoietin.

Indications for use

Treatment of patients with anemia in chronic renal failure:

– symptomatic anemia;

– anemia requiring transfusion.

Anemia resulting from tumor processes.

METHOD OF APPLICATION AND DOSES

As with any parenteral medicinal product, before use, EPOVITEN is checked for the absence of visible foreign particles and changes in the color of the solution. The initial dose is 50 IU/kg 3 times a week as a slow subcutaneous or intravenous injection over 1-2 minutes. Further dose increases depend on the response to initial therapy. If necessary, the dose can be increased by 25 IU/kg every 4 days. If the increase in hemoglobin exceeds 20 g/l after administration of 50 IU/kg, the dose should be adjusted by canceling one dose per week. The goal of treatment is to achieve a hemoglobin level of 100 g/l (hematocrit 30%). When a therapeutic effect is achieved, a maintenance dose of 25-50 IU/kg is usually prescribed 2-3 times a week. Patients starting therapy with a low hemoglobin level (60 g/L) should be given a higher maintenance dose than those starting treatment with a hemoglobin level of at least 80 g/L. The dose should be adjusted depending on age. In any case, the maximum dose should not exceed 200 IU/kg/day three times a week.

The drug EPOVITEN cannot be used in the form of intravenous infusions or mixtures with other drugs.

Subcutaneous administration. The maximum volume of subcutaneous injection in one area is 1 ml. If it is necessary to use large volumes, subcutaneous injection is carried out in several areas. The drug should be injected subcutaneously into the limbs or the anterior wall of the abdomen. Before or during treatment, it is necessary to determine the level of iron stores and, if necessary, prescribe iron supplements. In cases of aluminum poisoning or infectious diseases, the response may be delayed. Even if the patient does not require dialysis, the maintenance dose should be prescribed taking into account the severity of the anemic syndrome or age. It is reported that a hematocrit level of 36–38% can be maintained for more than 6 months.

OVERDOSE

The response to treatment with the drug is strictly individual and depends on the dose. In case of overdose, symptoms of hypertension may occur. If the hemoglobin level rises very quickly, then bloodletting may be indicated.

SIDE EFFECT

Shock: Since shock may occur in rare cases, the patient should be monitored closely. In the event of a health problem, the drug should be discontinued and appropriate treatment prescribed.

Cardiovascular system: increased blood pressure, vascular thrombosis, for example, in the area of the lacrimal duct, etc., tachycardia can sometimes occur.

Hypertensive encephalopathy: the drug should be prescribed with proper monitoring of blood pressure, hematocrit and other indicators, since when encephalopathy occurs,

Epaviten (Epargresiovit) ampoules

  • Product Code: Epaviten (Epargresiovit) ampoules
  • Availability: In Stock
  • $62.00

  • Ex Tax: $62.00